Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): evaluation report
01 - Pre-Meeting Briefing
02 - Submission from the technology manufacturer – Astellas
03 - NICE request to the manufacturer for clarification on their submission
04 - Manufacturer clarification response
05 - Consultee submission – Prostate Cancer UK
06 - Consultee submission – Prostate Cancer Support Federation
07 - Consultee submission – British Uro-Oncology Group
08 - Consultee submission – Royal College of Physicians
09 - Clinical expert personal perspective - Bahl
10 - Clinical expert personal perspective - Russell
11 - Patient expert personal perspective - Gunn
12 - Patient expert personal perspective – Watson
13 - Evidence Review Group report prepared by Kleijnen Systematic Reviews
14 - Manufacturer factual accuracy check of Evidence Review Group report
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
* Users of Google chrome should click the link below and then click the small PDF icon in the far right of the address bar to successfully access this document *
Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): evaluation report
18 October 2013 (4.6 Mb 53 sec) |
This page was last updated: 17 October 2013